KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Operations: 2018-2025

Historic Cash from Operations for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $22.6 million.

  • Castle Biosciences' Cash from Operations fell 3.03% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year increase of 4.56%. This contributed to the annual value of $64.9 million for FY2024, which is 1252.97% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Cash from Operations is $22.6 million, which was up 8.69% from $20.8 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Cash from Operations ranged from a high of $24.4 million in Q4 2024 and a low of -$25.4 million during Q1 2023.
  • Its 3-year average for Cash from Operations is $8.8 million, with a median of $18.6 million in 2023.
  • Per our database at Business Quant, Castle Biosciences' Cash from Operations slumped by 1,346.61% in 2021 and then spiked by 733.86% in 2024.
  • Castle Biosciences' Cash from Operations (Quarterly) stood at -$2.8 million in 2021, then tumbled by 115.75% to -$6.0 million in 2022, then surged by 409.78% to $18.6 million in 2023, then soared by 31.09% to $24.4 million in 2024, then declined by 3.03% to $22.6 million in 2025.
  • Its last three reported values are $22.6 million in Q3 2025, $20.8 million for Q2 2025, and -$6.0 million during Q1 2025.